Press Release: OyaGen : Tonix Pharmaceuticals Enters into Exclusive Worldwide Licensing Agreement with OyaGen to Develop Antiviral SARS-CoV-2 Inhibitor, TNX-3500, for the Treatment of COVID-19
Early Studies Show TNX-3500 Significantly Inhibits SARS-CoV-2, the Cause of COVID-19, and Potentiates RemdesivirEarly Studies Show TNX-3500 Significantly Inhibits SARS-CoV-2, the Cause of COVID-19, and Potentiates Remdesivir
Read full article »
OyaGen focuses on the discovery, development and commercialization of pharmaceutical therapies to exploit RNA editing and DNA editing enzymes.
Read more